199 related articles for article (PubMed ID: 21389870)
21. Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors.
Huck SP; Tang SC; Andrew KA; Yang J; Harper JL; Ronchese F
Cancer Immunol Immunother; 2008 Jan; 57(1):63-71. PubMed ID: 17609951
[TBL] [Abstract][Full Text] [Related]
22. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells.
Krug A; Rothenfusser S; Selinger S; Bock C; Kerkmann M; Battiany J; Sarris A; Giese T; Speiser D; Endres S; Hartmann G
J Immunol; 2003 Apr; 170(7):3468-77. PubMed ID: 12646607
[TBL] [Abstract][Full Text] [Related]
23. Combined encapsulation of a tumor antigen and immune cells using a self-assembling immunostimulatory DNA hydrogel to enhance antigen-specific tumor immunity.
Umeki Y; Saito M; Kusamori K; Tsujimura M; Nishimura M; Takahashi Y; Takakura Y; Nishikawa M
J Control Release; 2018 Oct; 288():189-198. PubMed ID: 30219278
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
[TBL] [Abstract][Full Text] [Related]
25. Liposome-encapsulated CpG enhances antitumor activity accompanying the changing of lymphocyte populations in tumor via intratumoral administration.
Kim DH; Moon C; Oh SS; Park S; Jeong JW; Kim S; Lee HG; Kwon HJ; Kim KD
Nucleic Acid Ther; 2015 Apr; 25(2):95-102. PubMed ID: 25692533
[TBL] [Abstract][Full Text] [Related]
26. T-cell mediated induction of allogeneic endothelial cell chemokine expression.
Kobayashi H; Koga S; Novick AC; Toma H; Fairchild RL
Transplantation; 2003 Feb; 75(4):529-36. PubMed ID: 12605122
[TBL] [Abstract][Full Text] [Related]
27. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
28. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
29. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes.
Raaijmakers TK; van den Bijgaart RJE; den Brok MH; Wassink M; de Graaf A; Wagenaars JA; Nierkens S; Ansems M; Scheffer GJ; Adema GJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461350
[TBL] [Abstract][Full Text] [Related]
30. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
Furumoto K; Soares L; Engleman EG; Merad M
J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
[TBL] [Abstract][Full Text] [Related]
31. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
32. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.
Kawarada Y; Ganss R; Garbi N; Sacher T; Arnold B; Hämmerling GJ
J Immunol; 2001 Nov; 167(9):5247-53. PubMed ID: 11673539
[TBL] [Abstract][Full Text] [Related]
33. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis.
Xu A; Zhang L; Yuan J; Babikr F; Freywald A; Chibbar R; Moser M; Zhang W; Zhang B; Fu Z; Xiang J
Cell Mol Immunol; 2019 Oct; 16(10):820-832. PubMed ID: 30467420
[TBL] [Abstract][Full Text] [Related]
34. Local Delivery of the Toll-Like Receptor 9 Ligand CpG Downregulates Host Immune and Inflammatory Responses, Ameliorating Established Leishmania (Viannia) panamensis Chronic Infection.
Ehrlich AK; Fernández OL; Rodriguez-Pinto D; Castilho TM; Corral Caridad MJ; Goldsmith-Pestana K; Saravia NG; McMahon-Pratt D
Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28052994
[TBL] [Abstract][Full Text] [Related]
35. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist.
Krieg AM; Efler SM; Wittpoth M; Al Adhami MJ; Davis HL
J Immunother; 2004; 27(6):460-71. PubMed ID: 15534490
[TBL] [Abstract][Full Text] [Related]
36. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.
Lapteva N; Aldrich M; Weksberg D; Rollins L; Goltsova T; Chen SY; Huang XF
J Immunother; 2009; 32(2):145-56. PubMed ID: 19238013
[TBL] [Abstract][Full Text] [Related]
37. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.
Heckelsmiller K; Rall K; Beck S; Schlamp A; Seiderer J; Jahrsdörfer B; Krug A; Rothenfusser S; Endres S; Hartmann G
J Immunol; 2002 Oct; 169(7):3892-9. PubMed ID: 12244187
[TBL] [Abstract][Full Text] [Related]
38. Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo.
Oh SM; Oh K; Lee DS
J Korean Med Sci; 2011 Oct; 26(10):1270-6. PubMed ID: 22022177
[TBL] [Abstract][Full Text] [Related]
39. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
Karan D; Krieg AM; Lubaroff DM
Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
[TBL] [Abstract][Full Text] [Related]
40. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model.
Hillinger S; Yang SC; Zhu L; Huang M; Duckett R; Atianzar K; Batra RK; Strieter RM; Dubinett SM; Sharma S
J Immunol; 2003 Dec; 171(12):6457-65. PubMed ID: 14662845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]